ACTICCA-1
The large European trial that will say whether the two-drug chemotherapy used for advanced disease beats capecitabine tablets as the treatment after surgery for bile duct and gallbladder cancer.
Overview
ACTICCA-1 opened in April 2014 comparing adjuvant gemcitabine and cisplatin with observation, and after BILCAP reported its control arm became capecitabine. The registry lists 789 actual participants, a status of active but not recruiting, and an estimated primary completion date of December 2025 (last updated 30 March 2025). Its readout is the next thing that could change adjuvant care for gallbladder cancer, where BILCAP's evidence is borrowed from a mixed biliary population.
Notes
top- Key facts: adjuvant gemcitabine and cisplatin for 24 weeks versus standard of care (observation, then capecitabine after BILCAP) within 16 weeks of macroscopically complete resection; two cohorts with separate sample sizes (cholangiocarcinoma 271 and muscle-invasive gallbladder carcinoma 154 evaluable) stratified by nodal status; primary endpoint disease-free survival; 789 enrolled at 67 sites in eight countries; primary completion December 2025; no results in Europe PMC or on the registry in September 2026. UK sites funded by Cancer Research UK.
- UK sites (24, registry): Hampshire Hospitals (Basingstoke), Queen Elizabeth Hospital Birmingham, Royal Bournemouth Hospital, Bristol Haematology and Oncology Centre, Addenbrooke's Cambridge, Velindre Cardiff, Western General Edinburgh, Beatson Glasgow, James Paget (Great Yarmouth), Royal Surrey Guildford, Princess Alexandra Harlow, Huddersfield Royal Infirmary, Guy's and St Thomas' London and others.
Similar pages
not linked directly; found by shared links- TrialSWOG S0809
Shares BILCAP, Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Capecitabine and the tag gallbladder-evidence.
- TrialGAIN (AIO/CALGP/ACO)
Shares Gemcitabine + cisplatin, Neoadjuvant / adjuvant / perioperative, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-evidence.
- TrialPOLCAGB
Shares Gemcitabine + cisplatin, Neoadjuvant / adjuvant / perioperative, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-evidence.
- TrialOPT-IN (EA2197)
Shares Gemcitabine + cisplatin, Neoadjuvant / adjuvant / perioperative, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-evidence.
- TrialHERIZON-BTC-01
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-evidence.
- Key paperReal-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer
Shares A ctDNA residual disease-guided adjuvant trial after gallbladder cancer resection, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-evidence.
- Key paperDetecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection
Shares A ctDNA residual disease-guided adjuvant trial after gallbladder cancer resection, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-evidence.
- Key paperHER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
Shares Report gallbladder cancer as its own population in every biliary trial, Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Biliary tract cancer (all types) and the tag gallbladder-evidence.